Featured | Mount Sinai Today

Preliminary Case Series Leads to New Questions About the Disease Progression of COVID-19 in Patients with Blood Clots in the Lung

Updated on Jun 30, 2022 | COVID-19, Featured, Research

Hooman D. Poor, MD, Assistant Professor of Medicine (Pulmonology, Critical Care and Sleep Medicine, and Cardiology)

A small, preliminary case series led by physicians at the Icahn School of Medicine at Mount Sinai found that five severely ill patients with the SARS-CoV-2 virus responded to the blood-clot-busting drug tPA when it was introduced as a life-saving measure. This response, and the large number of critically ill COVID-19 patients who have blood clots in their lungs, have raised new questions concerning the course of the disease and may present new possibilities for treating it.

“This case series pushes us to consider avenues of clinical investigation that are different from what they are now,” says the paper’s first author, Hooman D. Poor, MD, Assistant Professor of Medicine (Pulmonology, Critical Care and Sleep Medicine, and Cardiology). “Perhaps we should be looking at the disease from the standpoint of clots that form in the blood vessels and travel to the lungs.”

Dr. Poor says that more testing will be needed to determine whether the clots are the “inciting events in a subset of patients,” and not a complication that develops after these patients develop acute respiratory distress syndrome (ARDS). “ARDS looks the same, but it’s not,” he says. It requires “dramatically different treatments.”

According to the paper, the critically ill COVID-19 patients had relatively well-preserved lung mechanics, and did not develop stiffness of the lungs, despite severe gas exchange abnormalities. This feature is more consistent with pulmonary vascular disease and not with classic ARDS. The COVID-19 patients also demonstrated markedly abnormal coagulation with elevated D-dimers—small protein fragments present in the blood after a blood clot—and higher rates of venous thromboembolism, a condition where blood clots that form in the deep veins of the legs or groin travel and become lodged in the lungs.

Click here to read the paper titled “COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis.”

Mount Sinai’s paper cited autopsy studies from the SARS outbreak in the early 2000s, which revealed that patients had “pulmonary thrombi, pulmonary infarcts, and microthrombi in other organs.” SARS-CoV-1, the virus that caused SARS, and SARS-CoV-2, which causes COVID-19, belong to the same family of coronaviruses.

With mounting evidence that a consistent pattern of COVID-19 patients are presenting with blood clots, front-line clinicians at the Mount Sinai Health System and throughout the United States are reassessing and modifying existing guidelines that incorporate anticoagulation therapies.

Mount Sinai has provided treatment guidelines for its eight hospitals that address the significant role microthrombi—tiny clots composed of platelets—may play in patients with severe cases of COVID-19. The new guidelines help to inform clinical decision-making on administering anti-coagulation therapy for critically ill patients throughout the Health System. They call for patients who require hospitalization to be assessed for blood clots in their lungs by measuring their oxygen levels, testing for markers of clotting in their blood, and assessing their difficulty breathing or shortness of breath. Patients in intensive care units may also be eligible for a clinical trial at Mount Sinai that will examine the use of thrombolysis in respiratory failure due to COVID-19.

The recommendation was made by a panel of expert clinicians within Mount Sinai, and was based on published and rapidly emerging data, international and local experience, and autopsy reports.

Recently, the International Society on Thrombosis and Haemostatis recommended that all hospitalized COVID-19 patients, even those not in intensive care units, should receive prophylactic-dose low molecular weight heparin—a blood thinner—unless they have contraindications, such as active bleeding.

“If patients with COVID-19 show a small problem with their lungs, perhaps we should start them on blood thinners to prevent the clots from reaching the point where we have to administer tPA,” says Dr. Poor. “However, this treatment paradigm with early anticoagulation will need to be evaluated with well-designed clinical trials.”

A Snapshot of the Extraordinary Contributions of Mount Sinai Students in COVID-19 Efforts

Updated on Jun 30, 2022 | COVID-19, Featured, School

From left: Shravani Pathak (MS3), Samuel Paci (MS3), and PhD candidates Mark Roberto and Sindhura Gopinath, members of the PPE Task Force, inventoried PPE stock, coordinated with different floors, and distributed PPE across Mount Sinai West based on need.

In an extraordinary effort across the Icahn School of Medicine at Mount Sinai and its Graduate School of Biomedical Sciences in New York City, 200 students and postdoctoral fellows have volunteered more than 6,100 hours during a three-week period and continue to assist the Mount Sinai Health System during the staggering challenges of the COVID-19 crisis. As members of the Sinai Student Workforce, they have made an impact in a wide range of areas, from sourcing, acquiring and assembling personal protective equipment (PPE), to supporting clinical trials. An additional 450 student volunteers have since joined the effort.

Students are organized into task force teams working in the following areas: PPE, pharmacy, telehealth, administrative, operations, labs, and morale. The six-member COVID-19 Student Volunteer Leadership Team—Alexandra Agathis (MS3), Ben Asriel (MS4), Rohini Bahethi (MS3), James Blum (Scholarly Year), Zina Huxley-Reicher (MS4), and Shravani Pathak (MS3)—meets regularly with administration leadership to receive, triage, and coordinate requests from throughout the Health System. “Our students have become an essential part of the support system Mount Sinai needs to save lives and care for the communities it serves,” says David Muller, MD, Dean for Medical Education, and Professor and Marietta and Charles C. Morchand Chair in Medical Education.

“We know we’re making a huge difference because we can see it.” — Christopher Park (MS3), Icahn School of Medicine at Mount Sinai

Following is a snapshot of what they have accomplished.

The PPE Task Force, led by Annie Arrighi-Allisan (MS3) and Stephen Russell (MS3), sourced and acquired nearly 3,000 N95 masks, nearly 9,000 surgical masks, and 400 gowns. They assembled more than 1,500 durable, reusable face shields from 3M and distributed them to front-line health care providers, fitted staff with protective masks, and played an instrumental role in the distribution of 750,000 single-use face shields. Students worked in around-the-clock shifts to assemble more than 200 PPE go-bags for residents working at Elmhurst Hospital—which is part of a New York City integrated system of health care facilities that has been particularly hard-hit with COVID-19 cases, and with which Mount Sinai has an affiliation. In addition, the group trained more than 50 students to help fit clinical staff with new models of N95 respirators.

The Operations Task Force, led by Alexandra Capellini (MS2) and Christopher Park (MS3), delivered vital equipment, a task that requires unloading deliveries and assembling IV poles. One team assisted in rapidly engineering a method to transform 200 ResMed VPAP ST machines as a donation from Elon Musk, Chief Executive Officer of Tesla, Inc., as patient ventilators. They additionally helped write the assembly guide and operation instructions and assemble hundreds of units. Other teams provided support on clinical trials and promoted blood donations among their eligible classmates and peers.

From left: Jeremy Nussbaum (MS3), Marc Casale (MS3), Meygan Lackey (MS4), and Rebecca Rinehart (MS3) took inventory of COVID-19 medications, alerted staff of shortages, and distributed critical medications to hospital floors at Mount Sinai Beth Israel.

“This has been an intense, eye-opening experience and, for the first time, I’ve felt I was doing my small part to help with the response to the pandemic,” says postdoctoral fellow Dan Filipescu, PhD. “Prior to this, I had no idea how the day-to-day operations of a clinical trial worked, or the amount of effort that goes into caring for COVID-19 patients.”

Approximately 300 student volunteers from the Telehealth Task Force provided and obtained patient information—calling them with test results, calling hospitalized COVID-19 patients to gather information regarding emergency contacts, and triaging the palliative care hotline. Students were trained to know when to answer questions and when to refer them to their superiors. Using an online chat platform, they triaged patients with potential COVID-19 symptoms—providing them with additional information about the virus and how to self-isolate, and arranging virtual appointments with physicians, or sending them to the emergency room if necessary. To date, students have had more than 2,320 triage chats and test result updates with patients. “As future physicians, we entered this profession in order to help people,” says Harinee Maiyuran (MS4) who, with Sidra Ibad (MS1) leads the Telehealth Task Force. “Though we are unable to engage in direct clinical care, coordinating Telehealth has allowed me to not only participate but feel useful in these weeks of uncertainty and fear, and it has allowed me to give back to the New York City community that has become my home.”

Pharmacy was the first task force to send volunteers throughout the Mount Sinai Health System. Led by Benjamin Liu (MS3), the team has been troubleshooting Pyxis loading to help resolve medication supply shortfalls. When students at Mount Sinai Beth Israel made pharmacy leadership aware of a dwindling supply of Azithromycin, pharmacists were able to recommend a different medication for some patients to conserve their supply. Volunteers in the leadership suite assisted the Health System pharmacy director in researching treatment guidelines and protocols, and in reviewing charts to understand the impacts of the COVID-19 protocols.

Members of the Administrative Task Force, led by Christopher Ferrer (MS3) and Phillip Groden (MS3), handled remote medical scribe work and assisted outpatient practices with transitioning patients to Telehealth appointments. Working with the Department of Clinical Innovation, they reprogrammed tablets in every room and unit to allow for teleconferencing between patients, families, and staff. They have also been fielding offers of vital supplies and PPE and acquiring them for the frontlines. A group of student volunteers working with Materials Management leadership developed a system of creating inventories of crucial PPE supplies, leading to improvements in efficiency.

More than 40 student volunteers on the Labs Task Force, led by Michael Fernando (PhD2) and Maddie O’Brien (PhD2), have triaged more than 500 incoming requests for serum antibody testing. Working with the departments of Microbiology and Pathology, they have contacted approximately 200 donors with their results, and scheduled approximately 300 new participants prioritized for potential plasma donation. Their most recent initiative has 50 volunteers screening COVID-19 patients to assist the Operations team to prioritize candidates for plasma treatment.

Melissa Hill (MS3), left, and Sarah MacLean (MS3), learned that “it is impossible to breathe when wearing N95s correctly—and staff have to do it all day long.” They were members of a team that brought N95s and other PPE to Mount Sinai West.

As staff and volunteers throughout the Mount Sinai Health System work long hours under increasingly stressful conditions, keeping up morale plays a key role in the fight against coronavirus. The Morale Task Force, led by Ms. Arrighi-Allisan, Ella Cohen (MS1), and Katie Donovan (MS3), is charged with boosting morale among student volunteers and the greater Mount Sinai community. They have coordinated meal deliveries three days a week to all students remaining in nearby apartments, with leftovers going to residents, nurses, and other staff at The Mount Sinai Hospital. They distributed health kits containing a thermometer, pulse oximeter, a mask, and acetaminophen to students who are ill. They also fostered a sense of community through social media and blogs that highlight the achievements of student volunteers and have created an initiative to write letters to residents of nursing homes and other skilled nursing facilities.

Collaboration among peers extends beyond the Mount Sinai community and includes medical students from around the country. Students from the University of California, San Francisco, tweeted a seven-minute video to health care workers in New York City, showing solidarity, thanking them for their heroic efforts, and offering words of encouragement. “I am in awe of the way everyone has come together to fight this pandemic and all the hard work my peers have put into volunteering,” says Ms. Pathak. “I love collaborating with students from other schools as they reach out to me about how they can develop structures like our workforce in preparation for when the pandemic affects their communities.”

Adds Mr. Park about his experience on the Operations Task Force, “I think a lot of us are learning about the real meaning of resilience and adaptability by living it. We know we’re making a huge difference because we can see it. I am both inspired but also unsurprised by the student response, because this is the standard I knew that our student body functioned at and would strive for.”

Elmhurst Hospital During COVID-19, An Experience Like No Other

Updated on Jun 30, 2022 | COVID-19, Featured

Suresh K. Pavuluri, MD, MPH

The weekend of Saturday, March 14, marked a turning point for Suresh K. Pavuluri, MD, MPH, a second-year resident in Emergency Medicine at the Mount Sinai Health System, who was working in the Coronary Care Unit (CCU) at Elmhurst Hospital, a Mount Sinai affiliate. It was when the national discussion about the rising number of patients with COVID-19 became a deeply personal experience for him, and “everything just shifted quite dramatically,” he says.

Early that weekend, Dr. Pavuluri noted a couple of patients with suspected COVID-19 were being treated in the hospital’s Emergency Room and Medical Intensive Care Unit (MICU). That was consistent with his experience a week earlier, during his rotation at The Mount Sinai Hospital, where that hospital’s first COVID-19 patient had been treated and released.

But the trickle of patients at Elmhurst Hospital quickly changed into something very different as more patients started arriving. “It seemed to come out of nowhere,” he says. “Suddenly, everyone had COVID. It was as if this huge avalanche hit us and we were trying to dig our way out of it, trying to cope with all these patients. Initially, all the people who were under investigation for COVID were sent to the MICU. And that quickly changed because we didn’t have enough beds. So, then some of the floors were converted to handling these patients and others who had difficulty breathing.” The sickest patients, who required intubation to assist them with breathing, were sent to the intensive care units and what had been the CCU, where Dr. Pavuluri was busy tending to them.

Within days, the policy changed to not allowing any visitors or family members into the units with the sickest patients. “It was a way for us to protect the public, but it was also a way for us to protect our patients,” he says.

“So, all of a sudden, I could no longer have face-to-face conversations with family members, and we had to have discussions over the phone. It was difficult for the patients to not have their family members there because in intensive care there are so many nurses and doctors coming in and out. The lack of personalization was one of the hardest things about this. You can’t really comfort someone through a phone. The other part was that we spent a lot of time on the phone. We were receiving multiple phone calls a day from different family members. Obtaining consent to treat intensive care-level patients meant we had to track down family members as quickly as possible. Sometimes critically ill patients require multiple procedures. The patients were already intubated by the time they came upstairs. Some of the coronavirus patients were going into renal failure and needed dialysis. That is typical in the intensive care unit, but we never see the sheer volume of it. We never expected so many patients to require all of these things or this much attention. These were people in their 30s, 40s, 50s. We saw people in their mid-thirties with no prior medical problems. When this pandemic began, we thought it was going to be mostly elderly patients affected by this. Then we realized it’s anyone and everyone.”

During that turning point of a weekend at Elmhurst Hospital, Dr. Pavuluri says he began to hear the code “Team 700 to B4” on the overhead paging system more times than he could keep track of. It meant that a patient’s heart had stopped. At that point, Team 700 would rush into his unit and perform their assigned duties, from administering chest compressions to providing the medications needed to rescue the patient’s heart. “Before coronavirus took over our hospital, I may have heard this code once or twice a week,” he says. “But it became all too familiar. Sometimes, after several minutes, just when we felt defeated, the patient’s heart would start beating again and we’d sigh with relief and look at each other, acknowledging that it was just a matter of time until our next code.”

As the volume of patients entering Elmhurst Hospital increased, Dr. Pavuluri’s work schedule changed to meet the demand, from working every four days to 12-hour shifts. “We simply had to be resilient,” he says. “We had to be flexible and adapt to best serve our patients.”

More than a week later, Dr. Pavuluri developed COVID-19 too, and went home to nurse his splitting headaches, low-grade fever, exhaustion, chills, muscle aches, nausea, chest heaviness, congestion, and shortness of breath. He began to recover after five days. Eleven of his colleagues at Elmhurst Hospital also tested positive. By early April, Dr. Pavuluri was back at work, splitting his time in the Emergency Departments at Elmhurst Hospital and The Mount Sinai Hospital.

While he was home recuperating from COVID-19, Dr. Pavuluri had time to reflect.

“I can definitely say the experience will leave an impression on me and my colleagues for as long as we practice medicine. We did not anticipate this, and we were not prepared for this. I am really close to my family and they have been a great sounding board. My colleagues at work have been my great resource because they understand, they’ve been there. To be among the young doctors coming in and fighting the good fight—it’s been really gratifying. I am so proud to be among the nurses and doctors who are risking their lives every day in this pandemic. But there will be scars. It has been an experience like no other.”

Mount Sinai Turns Hundreds of Machines for Sleep Apnea into Hospital Ventilators, Shares Instructions Worldwide

Updated on Jun 30, 2022 | COVID-19, Featured, Research

Members of the Mount Sinai team that created the ventilator prototype seen here, included, from left, Drew Copeland, RPSGT; Thomas Tolbert, MD; Brian Mayrsohn, MD; and Hooman Poor, MD.

A team of pulmonologists, anesthesiologists, sleep and critical care specialists, and medical students at the Mount Sinai Health System are reconfiguring hundreds of donated machines that are typically used at home for sleep apnea and deploying them as ventilators to be used for severely ill patients who are hospitalized with COVID-19. Mount Sinai has shared the protocols and instructions with the Greater New York Hospital Association and the American Thoracic Society, as well as with other hospitals that are dealing with a national shortage of invasive ventilators during this pandemic. COVID-19 affects the respiratory system and has greatly increased the number of patients who are entering intensive care units and require assisted breathing.

When Mount Sinai received a shipment of 200 ResMed VPAP ST machines as a donation from Elon Musk, Chief Executive Officer of Tesla, Inc., in late March, a Health System task force was immediately organized to repurpose them. Within several days, the team put together a prototype that was tested in the Simulation HELPS Center at Mount Sinai, a unique laboratory run by the Department of Anesthesia that enables clinicians to simulate human responses to innovative technologies and procedures.

Three important modifications were made by the Mount Sinai team. First, a connection to an endotracheal tube replaced the typical mask that can present a risk of COVID-19 aerosolization; second, alarms that can alert clinicians if there is a problem with air flow were included; and third, the team enabled doctors and respiratory therapists to view and control the machine’s settings from outside the patient’s room, so they do not need to enter the room to make minor adjustments.

These VPAP machines will be used as an option under the current circumstances at Mount Sinai to prevent a shortage of invasive ventilators needed to serve the ongoing surge of patients. They are preferable to splitting invasive ventilators that serve two patients at the same time, a move that many hospitals are concerned they may have to pursue as a last resort.

Among the clinicians leading the effort at Mount Sinai is Charles A. Powell, MD, Janice and Coleman Rabin Professor of Medicine, Chief of the Division of Pulmonary, Critical Care, and Sleep Medicine, and Chief Executive Officer of the Mount Sinai – National Jewish Health Respiratory Institute. Dr. Powell says the machines can be used “in patients who do not require all the power of a regular ventilator, freeing up those conventional devices for the acutely ill.” He adds, “Our objective is to share our protocols widely with our colleagues around the globe facing this crisis. This project is a demonstration of the success of the team science collaborative research infrastructure at Mount Sinai that allowed us to make these innovations quickly.”

Any type of high-performing sleep device that delivers a comparable level of pressure to the ResMed VPAP ST model can work as a repurposed ventilator, according to Drew Copeland, Director of Operations for the Sleep Program at the Mount Sinai Health System. He says, “For many patients, this can save their life. We are not yet at a critical mass for ventilators but we may be getting there. This is a moving target. Hopefully, we can keep pace.”

After the first prototype was developed, Mr. Copeland enlisted a team of medical students from the Icahn School of Medicine at Mount Sinai to write the instructional user manual. They completed it in one day.

The students are now assembling the machines to be used throughout the Health System’s eight hospitals in the event of a shortage of invasive ventilators. Two floors of the medical school’s library have been set up as a staging area for the makeshift assembly line. The goal is to have all of the machines ready to be deployed by the end of this week.

To view the new Mount Sinai protocol, click below

Repurposing bi-level ventilators for use with intubated patients while minimizing risk to health care works during insufficient supply of conventional ventilation for patients with COVID-19

SARS-CoV2: How a Low-Powered Virus Turns Deadly

Mar 31, 2020 | COVID-19, Featured, Infectious Diseases, Research

File photo of the team from the tenOever Laboratory, from left to right: Kohei Oishi, PhD, Tristan Jordan, PhD, Daniel Blanco-Melo, PhD, Skyler Uhl, PhD candidate, Ben tenOever, PhD, Rasmus Moeller, PhD candidate, Maryline Panis, Lab Manager, Ben Nilsson-Payan, PhD, and Daisy Hoagland, PhD candidate

Early laboratory tests show the SARS-CoV2 virus, which leads to COVID-19, behaves very differently from the flu or common respiratory syncytial virus (RSV) in that it travels under the radar and enters human and animal cells quietly, eliciting a low-powered immune response that tends to fester, according to preliminary research led by Benjamin tenOever, PhD, the Fishberg Professor of Medicine, and Director of the Virus Engineering Center for Therapeutics and Research, at the Icahn School of Medicine at Mount Sinai. The observations, which provide a snapshot of how cells and organisms respond to the SARS-CoV2 virus, were based on studying RNA from live animal models and human cell lines. RSV often occurs in young children with symptoms that mimic the common cold.

“The take-home message of what we found so far is that the immune response to the virus is actually very muted,” says Dr. tenOever. In a typical reaction to the flu or RSV, the body secretes a whole family of proteins or interferons that assemble to take on a variety of functions to prepare for an imminent attack. Some of the interferons directly inhibit the virus. But with the SARS-CoV2 virus, Dr. tenOever says, “We see little to no evidence that the virus-infected cells are secreting these proteins. So a program that should be induced is not launching.” At most, the defense appears to be only 40 percent to 50 percent as strong as it would be for the flu or RSV.

The new virus behaves differently in another way, as well. Whereas the flu is particularly wily in dismantling the innate immune response in several places, SARS-CoV2 does not appear to do so, according to postdoctoral fellow Daniel Blanco Melo, PhD, who was a lead author of the study in Dr. tenOever’s lab. “We may find that the immune response is being blocked by this new virus too, but it won’t be in the same way as the flu,” he says.

According to the scientists, the preliminary findings show that the very stealth nature of SARS-CoV2 may actually account for its lethalness, a hypothesis that complements the virus’s long clinical progression, with many severely ill patients being hospitalized for more than 10 days. The hypothesis also supports the clinical evidence that patients need a strong immune system to fight COVID-19, the disease produced by the SARS-CoV2 virus. Under the leadership of Miriam Merad, MD, PhD, the Mount Sinai Professor in Cancer Immunology and Director of the Precision Immunology Institute, Mount Sinai is working to improve outcomes in critically ill patients who experience an excessive inflammatory response.

“It would almost appear that if you are a healthy individual under the age of 50 and you get this virus your immune system would have no problem tackling it, inhibiting it, and getting rid of it,” says Dr. tenOever. “But in older individuals and those who have comorbidities—those whose immune system is waning—our early data would suggest that their reduced immune system means they’re not aggressively neutralizing this virus, which leaves it to fester in the lungs and keep replicating.” This low-grade inflammation in the body allows the virus to remain under the radar for days as the patient’s lungs become increasingly damaged.

“Maybe what we’re seeing is a slow burn in some people that eventually takes its toll over 10 to 20 days,” says Dr. tenOever. “In the end, the immune system is reacting both to the virus and to the accumulating damage being done to the lungs. So the body goes into this mode of overly trying to repair itself from lungs that are leaking fluid and becoming hypoxic. By the time these patients come to the hospital it is more about controlling the inflammation to the damage induced by the virus than inhibiting the virus itself.”

Controlling Extreme Inflammation in Severe Cases of COVID-19 May Help Save Lives

Mar 27, 2020 | COVID-19, Featured, Research

Miriam Merad, MD, PhD, left, Director of the Precision Immunology Institute, with Adeeb Rahman, PhD, Director of the Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai.

Immunologists at the Icahn School of Medicine at Mount Sinai are playing a major role in managing the care of severely ill patients with COVID-19, who often experience an excessive inflammatory response to the disease that can ultimately overwhelm them.

Under the leadership of Miriam Merad, MD, PhD, the Mount Sinai Professor in Cancer Immunology and Director of the Precision Immunology Institute, Mount Sinai has created a quick test that monitors a patient’s inflammatory response to COVID-19 and helped launch a clinical trial that uses the drug sarilumab to manage these responses. The drug, manufactured by Regeneron Pharmaceuticals Inc., is typically used to treat rheumatoid arthritis. Dr. Merad says she may also roll out clinical trials that would test drugs used after CAR T cell adaptive therapies.

“Immunologists understand inflammation and know how to control it,” says Dr. Merad. “We developed a test with a three-hour turnaround time that we will repeat many times a day to see what type of inflammation the patient is developing and potentially guide treatment.” By identifying the features of severe immunological reactions in patients quickly, “we can speed the implementation of a cytokine blockade and significantly improve patient outcome.”

Cytokines are small proteins that modulate immunity. In trying to fight the COVID-19 virus the immune system may mount a major response, which can lead to excess inflammation that is also called a ‘cytokine storm.’ This overdrive reaction is happening in a range of COVID-19 patients, from the elderly to some young people with no apparent underlying health conditions.

“You need a strong immune response to fight the virus and this is why some people do well,” says Dr. Merad. “But others develop this storm of cytokines and this is what leads to fatalities. People are not dying from a virus that is running rampant in their bodies and killing tissue. We believe people are dying because of excessive inflammation. If we learn how to prevent this damaging immune response without compromising the fight against the virus we will be able to save many lives while waiting for curative treatment such as an antiviral drug or a vaccine.”

Benjamin K. Chen, MD, PhD

Dr. Merad adds, “There is urgency in learning how to best block the fatal inflammatory response.” To that end, she and other researchers are using the leading technology platform that she helped build in Mount Sinai’s Human Immune Monitoring Center, which allows them to “map with unprecedented depth the immune response to the virus in our patients.”

Benjamin K. Chen, MD, PhD, the Irene and Dr. Arthur M. Fishberg Professor of Medicine, and Vice Chair for Research in the Department of Medicine (Infectious Diseases), has been supporting the evolution of many proposed clinical trials with the help of leaders throughout the Mount Sinai Health System. Dr. Chen says there is limited but encouraging data to support cytokine blockers. Dr. Merad’s lab and the Human Immune Monitoring Center are uniquely capable of mapping out the “cytokine release profile,” he says. “With these trials we have the opportunity to measure those changes very carefully and decide what other trials or studies might be best to use for coronavirus. We are doing everything we can to support promising developments against COVID-19.”

Dr. Chen is working with Linda Rogers, MD, Associate Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), and Michele Cohen, Clinical Research Program Director in the Department of Medicine, who have been coordinating several major COVID-19 clinical trials at the Mount Sinai Health System. Judith A. Aberg, MD, the Dr. George Baehr Professor of Clinical Medicine and Chief of the Division of Infectious Diseases, Department of Medicine, is leading key clinical trials, including one for the antiviral drug remdesivir, made by Gilead Sciences. Remdesivir has shown promise in treating patients with COVID-19 and was developed in response to the Ebola crisis.

« Older Entries

Next Entries »